FDA asks drugmaker to stop selling opioid painkiller because benefits ‘may no longer outweigh its risks’

The FDA has requested that a major drugmaker pull one of its prescription painkillers because the agency is believes “the benefits of the drug may no longer outweigh its risks.”

The agency has asked Endo Pharmaceuticals to voluntarily stop selling the reformulated Opana ER, an extended-release painkiller that the FDA believes is being violently abused.

 

Read More